Wells Fargo upgraded Zymeworks (ZYME) to Overweight from Equal Weight with a price target of $33, up from $25. The firm believes the company’s gastroesophageal adenocarcinoma could drive upside in the shares. Th readout could generate enthusing for Zymeworks’ breast cancer opportunity, which Wells models at $1.5B and gives it a 55% probability of success.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Oracle initiated, Uber upgraded: Wall Street’s top analyst calls
- Zymeworks initiated with an Outperform at Citizens JMP
- Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences
- Zymeworks to Engage in Key Investor Conferences
- 3 Best Stocks to Buy Now, According to Top Analysts, 11/24/2025